This episode features an interview with Bruce Culleton, MD, CEO, ProKidney, a late clinical-stage biotech company focused on the development of a pioneering cell therapy candidate that aims to transform the treatment landscape for chronic kidney disease.
Prior to joining ProKidney in 2023, Dr. Culleton served as Vice President and General Manager at CVS Kidney Care and also worked in leadership roles at Becton Dickinson and Baxter healthcare. Before beginning his career in industry in 2007, Dr. Culleton was a Clinical Associate Professor in the Department of Medicine at the University of Calgary.
Chief Executive Officer
ProKidney
ProKidney’s lead product candidate, REACT, is an investigational cell therapy designed to stabilize or improve kidney function in patients with chronic kidney disease with diabetes as the primary cause. The candidate is currently being evaluated in Phase II and Phase III clinical trials.
To hear more about ProKidney’s cell therapy for chronic kidney disease, including developmental, manufacturing and regulatory considerations, tune into the episode.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN